Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NAVAN Technologies
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
NAVAN Technologies is a private, early-stage biotechnology company developing and commercializing a non-viral NanoStraw intracellular delivery platform that enables gentle, dosage-controlled delivery of diverse cargos (DNA, mRNA, proteins including Cas9) into hard-to-transfect primary human cells, primarily to support and co-develop next-generation cell and gene therapies rather than its own disclosed clinical pipeline.[1][2][3][4]
- Modalities
- DeviceNanoparticleNon-viral delivery platform
- Industry
- Drug Discovery Services
02
Partnerships
Strategic collaborators and partners in cell and gene therapy and regenerative medicine (names not publicly specified)[2][3][4]
Beyond the preview
Go deeper on NAVAN Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAVAN Technologies.